The IvyGene test is owned by Laboratory for Advanced Medicine. LAM is a biotechnology laboratory, specializing in revolutionary new technology, focused on the early intervention and detection of cancer. LAM was founded with a mission statement to make cancer testing available and affordable for everyone, and with that goal in mind, the company continues to develop, innovate, and research mechanisms to reinforce its founding beliefs.
Our company was founded on the efforts of two leading scientific teams. As the Director of the Institute of Genomic Medicine at the University of California, San Diego, Dr. Kang Zhang and his team determined that methylation was the best method to accurately detect cancers, and later developed the technology that is used in our laboratories today. In 2014, another team, led by Dr. Shu Li, formed Laboratory for Advanced Medicine to focus on the commercialization of methylation cancer detection testing with a US CLIA lab.
LAM incorporates the efforts of those teams. The company has CLIA and CAP certified laboratories, and cGMP facilities working towards bringing first-class technologies to the medical community. LAM operates globally with collaborations in the United States and China, including leading scientists, physicians, research institutions, and business leaders.
The company is headquartered in the United States with offices in California, Texas, and Indiana. In China, the company has offices in Beijing, Guangzhou and Bei Dai He.
The IvyGene Platform utilizes advanced sequencing techniques to analyze DNA Methylation patterns of cell-free DNA (cfDNA) in whole blood. The sequence along with the pattern of methylated DNA are consistent with cancer presence.This gives providers and patients access to important data regarding the health of patients at the time of testing. The IvyGene series of testing can confirm the presence of cancer, as early as stage 1, provides measurable information about cancer, and new commercial tests provide tissue-specific cancer confirmation; the IvyGene Liver test will be available in November 2018.
Unlike many genetic tests that use DNA to determine the propensity or possibility of developing cancer over time, the IvyGene test identifies DNA methylation patterns consistent with actual disease presence at the time of testing.
Mor-NuCo Enterprises, a subsidiary of LAM, is the laboratory that performs the IvyGene test. Mor-NuCo Enterprises’ Laboratory is located at 1201 Cumberland Avenue, Suite B, West Lafayette, IN 47906. Mor-NuCo Laboratory is CLIA Certified and CAP Accredited. CLIA #15D2033610